Showing 2341-2350 of 3356 results for "".
AbbVie's Skyrizi Approved, Brooke Shields Endorses SculpSure
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-abbvies-skyrizi-approved-brooke-shi/19607/Skyrizi, an interleukin-23 inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults. Brooke Shields is the face of the new “Be strong. Be sexy. Be confident” campaign for SculpSure, from Hologic’s Cynosure. The Noah Worcester Dermatological Society anEczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, andPipeline Watch: Sizing Up a Promising Phase III IL-17 Biologic
https://practicaldermatology.com/topics/psoriasis/pipeline-watch-sizing-up-a-promising-phase-iii-il-17-biologic/21214/Pipeline Watch is a new Q&A feature appearing periodically in Practical Dermatology® that explores the potential of therapeutic agents currently under investigation. In each edition, we will speak with investigators from manufacturing companies to gain insights about the development and investigComplications of Biologic Therapy for Psoriasis: Part II
https://practicaldermatology.com/topics/psoriasis/complications-of-biologic-therapy-for-psoriasis-part-ii/22039/Therapeutic success requires clinicians to understand emerging and established safety concerns.When Topicals Fail: The New IPC Consensus Every Clinician Should Know
https://practicaldermatology.com/programs/cme/when-topicals-fail-the-new-ipc-consensus-every-clinician-should-know/39967/Review IPC’s 2025 consensus guidance on reclassifying psoriasis severity and redefining failure of topical therapies.2022 in Review
https://practicaldermatology.com/topics/other-dermatology/2022-in-review/23833/The past year brought many new approvals and advances to dermatology for improved patient care.Therapeutic Review: A Host of New Treatments Emerged in 2018
https://practicaldermatology.com/topics/psoriasis/therapeutic-review-a-host-of-new-treatments-emerged-in-2018/20381/Here's a handy reference to new drugs and devices—and other key developments—this year.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-38/23774/Therapeutic Advances in the Topical Management of Acne
https://practicaldermatology.com/issues/supplements/therapeutic-advances-in-the-topical-management-of-acne/21618/MOC Sparks Anger, Frustration in Physician Community
https://practicaldermatology.com/topics/practice-management/moc-sparks-anger-frustration-in-physician-community/20898/Anti-MOC advocates wonder why they cannot get a seat at the table to discuss changing the system.